JP2016525092A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525092A5
JP2016525092A5 JP2016524330A JP2016524330A JP2016525092A5 JP 2016525092 A5 JP2016525092 A5 JP 2016525092A5 JP 2016524330 A JP2016524330 A JP 2016524330A JP 2016524330 A JP2016524330 A JP 2016524330A JP 2016525092 A5 JP2016525092 A5 JP 2016525092A5
Authority
JP
Japan
Prior art keywords
pyrrole
methyl
carboxylate
octahydropyrrolo
hexafluoropropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524330A
Other languages
English (en)
Japanese (ja)
Other versions
JP6647592B2 (ja
JP2016525092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/045145 external-priority patent/WO2015003002A1/en
Publication of JP2016525092A publication Critical patent/JP2016525092A/ja
Publication of JP2016525092A5 publication Critical patent/JP2016525092A5/ja
Application granted granted Critical
Publication of JP6647592B2 publication Critical patent/JP6647592B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524330A 2013-07-03 2014-07-01 ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 Expired - Fee Related JP6647592B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842543P 2013-07-03 2013-07-03
US61/842,543 2013-07-03
PCT/US2014/045145 WO2015003002A1 (en) 2013-07-03 2014-07-01 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Publications (3)

Publication Number Publication Date
JP2016525092A JP2016525092A (ja) 2016-08-22
JP2016525092A5 true JP2016525092A5 (https=) 2017-08-10
JP6647592B2 JP6647592B2 (ja) 2020-02-14

Family

ID=52144176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524330A Expired - Fee Related JP6647592B2 (ja) 2013-07-03 2014-07-01 ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用

Country Status (7)

Country Link
US (1) US9828379B2 (https=)
EP (1) EP3016653A4 (https=)
JP (1) JP6647592B2 (https=)
CN (1) CN105517547A (https=)
CA (1) CA2917050A1 (https=)
MX (1) MX2015017961A (https=)
WO (1) WO2015003002A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
TN2017000544A1 (en) * 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA124884C2 (uk) * 2016-11-16 2021-12-08 Лундбек Ла Джолла Ресеарч Центер, Інк. Фармацевтичні склади
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
RU2720203C1 (ru) * 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
NZ797702A (en) * 2017-03-13 2026-03-27 Lundbeck La Jolla Research Center Inc Dual magl and faah inhibitors
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
CN111032034B (zh) * 2017-08-29 2023-05-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
BR112020005720A2 (pt) * 2017-09-29 2020-10-20 Takeda Pharmaceutical Company Limited composto ou sal, medicamento, métodos para inibir monoacilglicerol lipase e para a profilaxia ou o tratamento de doença de alzheimer, doença de parkinson, doença de huntington, esclerose lateral amiotrófica, esclerose múltipla, distúrbio de ansiedade, dor, epilepsia ou depressão, e, uso do composto ou sal.
GEP20227443B (en) 2018-05-15 2022-11-25 H Lundbeck As Magl inhibitors
MX2021000549A (es) * 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
WO2021062232A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for reducing rewarding effects of morphine without affecting its analgesic effects
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
EP4317153A4 (en) * 2021-04-01 2024-02-21 ONO Pharmaceutical Co., Ltd. Abhd6 antagonist
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト,インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
ES2585806T3 (es) * 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2011109277A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
EP2444084A1 (en) * 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用

Similar Documents

Publication Publication Date Title
JP2016525092A5 (https=)
JP2018500376A5 (https=)
US20230234958A1 (en) Shp2 phosphatase inhibitors and methods of use thereof
JP6435323B2 (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2013523884A5 (https=)
DK2552920T3 (en) UNKNOWN UNKNOWN NK-3 RECEPTOR SELECTIVE ANTAGONIST RELATIONS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTOR-MEDIUM DISORDERS
HRP20200575T1 (hr) Spojevi karbamata i postupci pripremanja i korištenja istih
JP2011511034A5 (https=)
JP2015510938A5 (https=)
JP2021506858A5 (https=)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
JP2011516558A5 (https=)
FI3436461T3 (fi) Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
US20230406860A1 (en) Heterocyclic spiro compounds and methods of use
JP2014506929A5 (https=)
JPWO2020005873A5 (https=)
JP2017530960A5 (https=)
JP2015522002A5 (https=)
RU2017105296A (ru) Новые соединения
HRP20210935T1 (hr) Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
RU2005117383A (ru) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
JPWO2020005877A5 (https=)
JP2014511355A5 (https=)
JP2022502490A5 (https=)